Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone

Free Abstracts

  Gastric Cancer

  Free Subscription


1 Am J Clin Oncol
1 Anticancer Res
3 BMC Cancer
1 Br J Cancer
1 Cancer
3 Gastrointest Endosc
1 J Surg Oncol
2 Lancet Oncol
1 PLoS One
1 World J Surg

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Am J Clin Oncol

  1. PALIGA A, Marginean H, Tessier-Cloutier B, Purgina B, et al
    The Prognostic Significance of c-MET and EGFR Overexpression in Resected Gastric Adenocarcinomas.
    Am J Clin Oncol. 2017;40:543-551.
    PubMed     Text format     Abstract available

    Anticancer Res

  2. ANDREOU A, Pesthy S, Struecker B, Dadras M, et al
    Incidence and Risk Factors of Symptomatic Hiatal Hernia Following Resection for Gastric and Esophageal Cancer.
    Anticancer Res. 2017;37:7031-7036.
    PubMed     Text format     Abstract available

    BMC Cancer

  3. KELLER S, Kneissl J, Grabher-Meier V, Heindl S, et al
    Evaluation of epidermal growth factor receptor signaling effects in gastric cancer cell lines by detailed motility-focused phenotypic characterization linked with molecular analysis.
    BMC Cancer. 2017;17:845.
    PubMed     Text format     Abstract available

  4. KAWAMOTO Y, Komatsu Y, Yuki S, Sawada K, et al
    Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer.
    BMC Cancer. 2017;17:837.
    PubMed     Text format     Abstract available

  5. CAO GD, Chen K, Chen B, Xiong MM, et al
    Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients.
    BMC Cancer. 2017;17:841.
    PubMed     Text format     Abstract available

    Br J Cancer

  6. WANG X, Zhao DB, Yang L, Chi Y, et al
    S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study.
    Br J Cancer. 2017 Dec 12. pii: bjc2017424. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  7. JIM MA, Pinheiro PS, Carreira H, Espey DK, et al
    Stomach cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:4994-5013.
    PubMed     Text format     Abstract available

    Gastrointest Endosc

  8. LIBANIO D, Dinis-Ribeiro M
    Gastroscopy and gastric cancer-related mortality: Time to change recommendations regarding screening?
    Gastrointest Endosc. 2018;87:128-130.
    PubMed     Text format    

  9. KANESAKA T, Lee TC, Uedo N, Lin KP, et al
    Computer-aided diagnosis for identifying and delineating early gastric cancers in magnifying narrow-band images.
    Gastrointest Endosc. 2017 Dec 7. pii: S0016-5107(17)32535.
    PubMed     Text format     Abstract available

  10. SVERDEN E, Brusselaers N, Wahlin K, Lagergren J, et al
    Time latencies of Helicobacter pylori eradication after peptic ulcer and risk of recurrent ulcer, ulcer adverse events, and gastric cancer: a population-based cohort study.
    Gastrointest Endosc. 2017 Dec 9. pii: S0016-5107(17)32543.
    PubMed     Text format     Abstract available

    J Surg Oncol

  11. IKOMA N, Cloyd J, Badgwell BD, Agnes A, et al
    Clinical features and survival of gastric cancer patients with DNA mismatch repair deficiency.
    J Surg Oncol. 2017 Dec 11. doi: 10.1002/jso.24926.
    PubMed     Text format     Abstract available

    Lancet Oncol

  12. DOI T, Shitara K, Naito Y, Shimomura A, et al
    Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
    Lancet Oncol. 2017;18:1512-1522.
    PubMed     Text format     Abstract available

  13. CATENACCI DVT, Tebbutt NC, Davidenko I, Murad AM, et al
    Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2017;18:1467-1482.
    PubMed     Text format     Abstract available

    PLoS One

  14. ZHI P, Shi J, Liu F
    Genetic variations at 8q24 and gastric cancer susceptibility: A meta-analysis study.
    PLoS One. 2017;12:e0188774.
    PubMed     Text format     Abstract available

    World J Surg

  15. MATSUDA T, Takeuchi H
    Clinicopathological Characteristics and Prognostic Factors of Patients with Siewert Type II Esophagogastric Junction Carcinoma: A Retrospective Multicenter Study: Reply.
    World J Surg. 2017;41:1395.
    PubMed     Text format    

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.